NIH researchers who intravenously delivered a cancer vaccine to mice report that it increased the number of T cells able to combat tumours.
List view / Grid view
US National Institutes of Health (NIH)
Texas Biomed and The Access to Advanced Health Institute have been granted $3.5 million to initiate tuberculosis vaccine research, which includes using genetically diverse animal models.
Researchers screened biologically active small molecules, finding several compounds with the ability to induce training effects on macrophages.
A bioluminescence resonance energy transfer sensor has been developed to report changes in intracellular Ca2+ concentrations during screening.
Researchers have developed a 3D structure that allows them to see how and where disease mutations on the twinkle protein can lead to mitochondrial diseases.
A research centre based at the University of Kansas has been awarded $6.6 million to create lab-on-a-chip technology for medical tests.
A new study has highlighted that gene expression profiling could enable rapid identification of anti-tumour immune cells for personalised immunotherapy.
Researchers have identified potential age-related macular degeneration drugs using a novel stem-cell based research tool.
A new potential mRNA vaccine that delivers instructions for making two key HIV proteins has been tested in mice and rhesus macaques.
In this article, Drug Target Review’s Victoria Rees explores a new screening platform that assesses the biological activity of molecules to identify potential drugs. Using their new technique, researchers from the US National Institutes of Health (NIH) identified potential COVID-19 therapeutics.
Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.
The experimental drug TEMPOL has demonstrated antiviral activity against COVID-19 in a pre-clinical study in cell cultures.
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.